Health Condition 1: K831- Obstruction of bile duct
Conditions
Interventions
Intervention1: Propofol Infusion Along with Dexmedetomidine Bolus And Infusion at 0.25 mcg/kg/hour.
: Patient Undergoing ERCP Will be Given Sedation With Propofol And Dexmedetomidine Both. Propofol I
Sponsors
INSTITUTE OF LIVER AND BILIARY SCIENCES
Eligibility
Inclusion criteria
Inclusion criteria: All Patients Undergoing ERCP and Belonging To American Society of Anesthesiologist Physical Status 1 and 2.
Exclusion criteria
Exclusion criteria: Patient Refusal, Allergy To Propofol Or Dexmedetomidine, Anticipated Difficult Airway, Obesity With Bmi More Than 40, Baseline Severe Bradycardia (Hr Less Than 50/ Min), Decompensated Liver Disease Belonging To Child B And Child C Status, Uncontrolled Hypotension (Mean Arterial Pressure Less Than 65 Mmhg Despite Fluids/pressors),American Society of Anesthesiologist Physical Status 3 and 4, Pregnant Females.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To Determine Mean Target Plasma Propofol Concentration (CP) Required To Maintain Bispectral Index Value Of 60 70 While Using Combined Propofol Target Controlled Infusion (Marsh) Plus Dexmedetomidine Infusion With Two Different Dosages Of Dexmedetomidine During Ercp. Timepoint: At The End of ERCP (After Averaging All The Values Taken During The Procedure Every 5 Mins) | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to achieve target BIS value of 60- 70 across three groups. Timepoint: At the begining of ERCP;To compare the incidence of hypotension, bradycardia, desaturation, respiratory depression and apnea across three groups.Timepoint: During the procedure and till recovery;To compare time to achieve BIS of 80 after stopping of infusions and time to clinical recovery based on Modified observer assessment of alertness/sedation scale.Timepoint: During the procedure and till recovery;To compare endoscopist satisfaction score across three groups.Timepoint: At the end of ERCP;To compare propofol consumption across three groups.Timepoint: At the end of ERCP | — |
Countries
India
Contacts
Public ContactSURAJ VERMA
Institute of Liver and Biliary Sciences
Outcome results
None listed